long term effects of retatrutide experimental weight-loss drug side and concerns Retatrutide: What We Know About

Market Scope Market Dynamics Drivers Burgeoning demand for potent metabolic therapies The rising cases of type 2 diabetes and obesity in Australia, growing trend of early diagnosis for timely interventions, changing lifestyles and the need for effective treatment strategies to lower the disease burden and improving patient health outcomes are boosting the demand for GLP-1 receptor agonists in Australia

Lei Qian from Innovent Biologics, stated, "Mazdutide represents the next-generation dual GCG/GLP-1 receptor agonist

But its known as the glucagon like peptide, the GLP one

However, competition from Eli Lilly has caused sales to decline this year, with the company initially expecting up to a 13% fall in revenue for the first time since it introduced the weight loss drugs